AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00743873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of 6 cc of saline into injured area
Study NCT02391194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-620
Study NCT03541408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard Of Care without Preventative Delirium Protocol
Study NCT03541408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventative Delirium Protocol
Description: Preventative Delirium Protocol
Study NCT03376243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIPIKAR BAUME AP+ emollient
Description: Structured education on prevention guidelines
Study NCT00350766 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation
Description: Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
Study NCT00350766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation
Description: Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
Study NCT02942758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose Azacitidine
Description: Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
Study NCT02942758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 45 mg p.o. continuously from day 1
Study NCT02942758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
Study NCT02942758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose AZA
Description: Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
Study NCT00940628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: mildly hypocaloric diet and physical exercise
Study NCT00940628 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet and Exercise
Description: mildly hypocaloric diet and physical exercise
Study NCT00940628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat [Xenical]
Description: 120mg po tid
Study NCT03077919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% ropivacaine
Study NCT03077919 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: preservative-free normal saline
Study NCT03079063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa, biosimilar
Description: Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
Study NCT03079063 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novoseven
Description: Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
Study NCT04628429 — intervention group
Intervention type: DRUG
Intervention: Erenumab
Description: anti-CGRP-receptor monoclonal anti-body
Study NCT03783767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Intervention
Description: Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
Study NCT03694509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast tea with full fat milk
Description: Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
Study NCT00004918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1 leukemia peptide vaccine
Description: Given SC
Study NCT00004918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study NCT01826929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Study NCT01420770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT03383276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Description: custom eye drop to be applied to the left eye.
Study NCT03770806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
Study NCT03770806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Nerve Block
Description: Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
Study NCT03770806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Block
Description: routine iv and oral pain medication alone-observation only
Study NCT03864406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Each tablet of Tybost contains 150 mg of cobicistat.
Study NCT03864406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat
Description: Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
Study NCT03864406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Each tablet of Xarelto contains 10 mg of rivaroxaban.
Study NCT03237325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX942
Description: 1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
Study NCT03237325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
Study NCT00944528 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Single dose or radiation in 15Gy, 18Gy or 21Gy
Study NCT00004918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT02329951 — intervention group
Intervention type: PROCEDURE
Intervention: Facet intervention
Description: Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
Study NCT02329951 — intervention group
Intervention type: PROCEDURE
Intervention: Sacroiliac joint injection
Description: Injection of steroid and local anesthetic into SI joint
Study NCT03694509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water 250ml.
Study NCT02090088 — intervention group
Intervention type: DRUG
Intervention: Not applicable- observational study
Study NCT03379337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dental imaging
Description: The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
Study NCT03349021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bougiecap
Description: Treatment of esophagel Stenosis by Bougiecap
Study NCT02969382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
Study NCT02969382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: One Placebo capsule daily for 4 weeks
Study NCT04705792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stools
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stools
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saliva
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
Study NCT02329951 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural steroid injection
Description: Transforaminal or interlaminar injection of steroid epidurally
Study NCT02208427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine and Isoniazid for 3 months
Description: weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
Study NCT02208427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid for 9 months
Description: daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
Study NCT03876795 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Concentrate
Description: Bone Marrow Concentrate injection
Study NCT03876795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate
Description: Bone Marrow Concentrate injection
Study NCT00422058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c. (under the skin) once daily
Study NCT00422058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orlistat
Description: 120 mg capsule. Administered thrice daily
Study NCT00422058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected s.c. (under the skin) once daily
Study NCT00422058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Injected s.c. (under the skin) once daily
Study NCT00482664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: Tablets for oral administration
Study NCT00482664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study NCT01756651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin
Description: comparison of Intranasal fentanyl 100mcg vs 200 mcg.
Study NCT02316574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills Therapy
Description: Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use.
Study NCT03081962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bundle
Description: Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
Study NCT03081962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
Study NCT03081962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Saliva
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
Study NCT04628429 — intervention group
Intervention type: DRUG
Intervention: Galcanezumab
Description: anti-CGRP-ligand monoclonal anti-body
Study NCT04628429 — intervention group
Intervention type: DRUG
Intervention: Fremanezumab
Description: anti-CGRP-ligand monoclonal anti-body
Study NCT00932906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit
Study NCT00932906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard training
Description: Instructor-based training meeting ERC directions
Study NCT04062591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam group
Description: patients will receive 0.4 mg/kg piroxicam IM
Study NCT04062591 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: saline IM in the same dose of piroxicam
Study NCT03738618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed
Study NCT03738618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Study NCT02722200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
Study NCT02722200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
Study NCT04295239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Pre and Post operative MRI
Study NCT00640848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 400 mg in two treatment sequences
Study NCT00640848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 200 mg in two treatment sequences
Study NCT00640848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 100 mg in two treatment sequences
Study NCT00640848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 50 mg mg in two treatment sequences
Study NCT00640848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 1000 mg in two treatment sequences
Study NCT00771888 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lanreotide
Description: lanreotide
Study NCT03605446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits
Study NCT03605446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits
Study NCT04566601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet
Study NCT04566601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT02333799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets
Study NCT02333799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200mg tablets
Study NCT02333799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Scored 600mg tablets
Study NCT04160858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week \& 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
Study NCT04160858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Wait-list control
Study NCT02039284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SES
Description: SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
Study NCT02039284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT
Description: The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.